Snead D, Matyszewski M, Dickey A, Lin Y, Leschziner A, Reck Peterson S. Structural basis for Parkinson's disease-linked LRRK2's binding to microtubules. Nat Struct Mol Biol. 2022;29:1196-1207 pubmed publisher

Fdez E, Madero Pérez J, Lara Ordóñez A, Naaldijk Y, Fasiczka R, Aiastui A, et al. Pathogenic LRRK2 regulates centrosome cohesion via Rab10/RILPL1-mediated CDK5RAP2 displacement. iScience. 2022;25:104476 pubmed publisher

Lin Y, Lin C, Ho E, Ke Y, Petridi S, Elliott C, et al. Glial Nrf2 signaling mediates the neuroprotection exerted by Gastrodia elata Blume in Lrrk2-G2019S Parkinson's disease. elife. 2021;10: pubmed publisher

Oliveira S, Dionísio P, Gaspar M, Correia Guedes L, Coelho M, Rosa M, et al. miR-335 Targets LRRK2 and Mitigates Inflammation in Parkinson's Disease. Front Cell Dev Biol. 2021;9:661461 pubmed publisher

Myasnikov A, Zhu H, Hixson P, Xie B, Yu K, Pitre A, et al. Structural analysis of the full-length human LRRK2. Cell. 2021;184:3519-3527.e10 pubmed publisher

Neethling A, Engelbrecht L, Loos B, Kinnear C, Theart R, Abrahams S, et al. Wild-type and mutant (G2019S) leucine-rich repeat kinase 2 (LRRK2) associate with subunits of the translocase of outer mitochondrial membrane (TOM) complex. Exp Cell Res. 2019;375:72-79 pubmed publisher

Greggio E, Jain S, Kingsbury A, Bandopadhyay R, Lewis P, Kaganovich A, et al. Kinase activity is required for the toxic effects of mutant LRRK2/dardarin. Neurobiol Dis. 2006;23:329-41 pubmed